Fabtech Technologies Makes Weak Debut with 4.45% Discount, Lists at ₹182.50 Against Moderate Subscription

Fabtech Technologies Limited, the biopharma engineering company offering turnkey cleanroom facilities, modular systems, and customised engineering solutions for pharma and biotech sectors, made a disappointing debut on BSE and NSE on October 7, 2025. After closing its IPO bidding between September 29 and October 1, 2025, the company commenced trading flat at ₹191 but declined to ₹182.50 with losses of 4.45%.

Fabtech Technologies Listing Details

Fabtech Technologies Limited launched its IPO at ₹191 per share with a minimum investment of 75 shares costing ₹14,325. The IPO received moderate response with a subscription of 2.04 times — retail investors at 2.09 times, NII at 1.97 times, and QIB at 2.02 times.

First-Day Trading Performance Outlook

Invest in Indian Markets and Unlock Future Potential With 5paisa!

Open Account Now

Listing Price: Fabtech Technologies share price opened at ₹191, representing no premium from the issue price of ₹191, and declined to ₹182.50, delivering losses of 4.45% for investors, reflecting cautious market sentiment towards the biopharma engineering sector.

Growth Drivers and Challenges

Growth Drivers:

• Comprehensive Turnkey Solutions: End-to-end services spanning design, engineering, manufacturing, installation, and project management with expertise in cleanroom technology, HVAC systems, and process equipment for the bio-pharma manufacturing lifecycle.
• Diversified Service Offerings: Clean water solutions (purified water, pure steam, water for injections with 500–50,000 LPH flow rates) and clean air solutions serving life sciences, food and beverage, IT, semiconductor, and aeronautics industries.
• Strong Financial Performance: Impressive PAT growth of 70% to ₹46.33 crore and revenue growth of 46% to ₹335.94 crore in FY25, healthy ROE of 30.46%, solid ROCE of 24.46%, and strong margins with a PAT margin of 13.83%.

Challenges:

• Full Valuation Metrics: Post-issue P/E of 18.28x and price-to-book value of 3.57x appearing fully priced, requiring a sustained high growth trajectory to justify premium valuation in the specialised engineering solutions space.
• Limited Operating History: Company incorporated only in 2018 with a relatively short track record, workforce of 185 employees as of July 2025, and operating in a competitive turnkey engineering solutions segment requiring continuous execution excellence.

Utilisation of IPO Proceeds

• Working Capital Requirements: ₹127.00 crore for funding working capital requirements supporting project execution, inventory management, and operational scale-up across the biopharma engineering solutions business.
• Inorganic Growth Initiatives: ₹30.00 crore for pursuing acquisitions enabling business expansion, technology enhancement, and market reach extension in the specialised engineering solutions segment.
• General Corporate Purposes: Supporting business operations, strategic initiatives, and expansion activities for sustained growth in the biopharma engineering sector.

Financial Performance of Fabtech Technologies

• Revenue: ₹335.94 crore for FY25, showing impressive growth of 46% from ₹230.60 crore in FY24, reflecting strong market demand and successful business scaling in turnkey biopharma engineering solutions.
• Net Profit: ₹46.33 crore in FY25, representing exceptional growth of 70% from ₹27.22 crore in FY24, indicating substantial operational leverage and significant margin expansion benefits in specialised engineering services.
• Financial Metrics: Healthy ROE of 30.46%, solid ROCE of 24.46%, moderate debt-to-equity ratio of 0.32, impressive PAT margin of 13.83%, moderate EBITDA margin of 14.07%, and estimated market capitalisation of ₹811.25 crore.